Figure 1.

Kaplan-Meier survival curves demonstrating trend towards increased colectomy (a, p = 0.06) and UC-related hospitalization (b, p = 0.02) rate during maintenance infliximab or adalimumab for 57 ulcerative colitis patients starting anti-TNF therapy within three years of diagnosis (blue) compared to 57 patients starting anti-TNF therapy more than three years after diagnosis (red). There is no difference in secondary loss of response requiring dose escalation between early and late anti-TNF initiators (c, p = 0.70). Hashed lines indicate censored cases (which did not meet primary outcome to last follow-up).